Joanna Horobin

Joanna Horobin M.B., Ch.B. is an accomplished drug developer and biotech leader with over 35 years of experience in the pharmaceutical and biotech sector. Dr. Horobin serves as a Non-Executive Director on the boards of Kymera Therapeutics Inc. (NASDAQ, KYMR), Nordic Nanovector ASA (Oslo, NANO) and Vyant Bio (NASDAQ, VYNT). Joanna has held multiple C-suite roles in biotech companies in the USA, most recently as the Chief Medical Officer at Idera Pharmaceuticals Inc. (NASDAQ, IDRA) and was also the CEO of Syndax Pharmaceuticals (NASDAQ, SNDX).

Joanna entered the pharma industry in 1982, initially in clinical development roles resulting in the development and launch of 8 products in the anti-infective, cardiovascular and anti-inflammatory categories. Moving to general management roles of increasing responsibility in the UK, France and USA, she shifted to cancer drug development which has been her major career focus. She led a joint venture between Rhone Poulenc and Chugai to develop and launch Chugai’s gCSF product Granocyte in Europe and, as VP Oncology, launched Rhone Poulenc Rorer (now Sanofi) as a major player in oncology with the global launch of Taxotere.

After gaining her medical qualifications from the University of Manchester Medical School in the United Kingdom Dr. Horobin initially pursued a career as a General Practitioner, gained membership of the Royal College of General Practitioners and practiced as a GP in London.